MA27018A1 - Forme dosifiee pharmaceutique de mesylate de nelfinavir amorphe. - Google Patents

Forme dosifiee pharmaceutique de mesylate de nelfinavir amorphe.

Info

Publication number
MA27018A1
MA27018A1 MA27379A MA27379A MA27018A1 MA 27018 A1 MA27018 A1 MA 27018A1 MA 27379 A MA27379 A MA 27379A MA 27379 A MA27379 A MA 27379A MA 27018 A1 MA27018 A1 MA 27018A1
Authority
MA
Morocco
Prior art keywords
dosage form
pharmaceutical dosage
nelfinavir mesylate
amorphous nelfinavir
amorphous
Prior art date
Application number
MA27379A
Other languages
English (en)
Inventor
Martin Howard Unfeld
Wantanee Phuapradit
Navnit Hargovindas Shah
Lin Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA27018A1 publication Critical patent/MA27018A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA27379A 2001-05-03 2003-11-03 Forme dosifiee pharmaceutique de mesylate de nelfinavir amorphe. MA27018A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03

Publications (1)

Publication Number Publication Date
MA27018A1 true MA27018A1 (fr) 2004-12-20

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27379A MA27018A1 (fr) 2001-05-03 2003-11-03 Forme dosifiee pharmaceutique de mesylate de nelfinavir amorphe.

Country Status (36)

Country Link
US (1) US7014866B2 (fr)
EP (1) EP1390063B1 (fr)
JP (1) JP4101661B2 (fr)
KR (1) KR100554816B1 (fr)
CN (1) CN1255185C (fr)
AR (1) AR034320A1 (fr)
AT (1) ATE282428T1 (fr)
BG (1) BG108311A (fr)
BR (1) BR0209325A (fr)
CA (1) CA2444116C (fr)
CZ (1) CZ20033211A3 (fr)
DE (1) DE60201988T2 (fr)
EA (1) EA006627B1 (fr)
EC (1) ECSP034827A (fr)
ES (1) ES2231717T3 (fr)
GE (1) GEP20053466B (fr)
GT (1) GT200200079A (fr)
HR (1) HRP20030873B1 (fr)
HU (1) HU229938B1 (fr)
IL (2) IL158306A0 (fr)
IS (1) IS7010A (fr)
JO (1) JO2401B1 (fr)
MA (1) MA27018A1 (fr)
MX (1) MXPA03009971A (fr)
MY (1) MY128509A (fr)
NO (1) NO20034689D0 (fr)
NZ (1) NZ528689A (fr)
PA (1) PA8544501A1 (fr)
PE (1) PE20021159A1 (fr)
PL (1) PL366998A1 (fr)
PT (1) PT1390063E (fr)
RS (1) RS83503A (fr)
SK (1) SK14572003A3 (fr)
TW (1) TWI234461B (fr)
UA (1) UA76463C2 (fr)
WO (1) WO2002089835A2 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (fr) 1999-11-12 2006-06-14 Abbott Laboratories Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (fr) * 2002-01-28 2003-07-28 Pfizer Inc. Comprime de nelfinavir a dose elevee et methode de production connexe
CN100475209C (zh) * 2003-07-15 2009-04-08 阿利健制药有限公司 抗冠状病毒剂
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
EP2586444B1 (fr) * 2004-12-03 2019-09-25 Merck Sharp & Dohme Corp. Formulation pharmaceutique d'inhibiteurs de l'intégrase du VIH de type carboxamide contenant une composition de contrôle de vitesse de libération
SI1928427T1 (sl) * 2005-09-23 2010-03-31 Hoffmann La Roche Nove formulacije za doziranje
KR20080089344A (ko) * 2005-12-14 2008-10-06 에프. 호프만-라 로슈 아게 Ｃ형 간염 바이러스(ｈｃｖ) 전구약물 제형
ES2350497T3 (es) * 2005-12-14 2011-01-24 F. Hoffmann-La Roche Ag Formulación de profármacos para el vhc.
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
US20100038816A1 (en) * 2006-08-16 2010-02-18 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
EP2112925A4 (fr) * 2006-11-15 2013-01-09 Abbott Lab Formulations de dosage pharmaceutique solides
WO2008115442A1 (fr) 2007-03-16 2008-09-25 Concert Pharmceuticals, Inc. Inhibiteurs de protéine de transfert d'ester de cholestérol
KR20100012031A (ko) * 2007-04-19 2010-02-04 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
WO2008133949A1 (fr) 2007-04-25 2008-11-06 Concert Pharmaceuticals, Inc. Analogues de cilostazol
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
US8567657B2 (en) * 2007-04-30 2013-10-29 Mtj Consulting Services Inc. Coiled tubing with retainer for conduit
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
MX341177B (es) 2007-05-01 2016-08-10 Concert Pharmaceuticals Inc Compuestos de morfina.
CN102964302B (zh) 2007-05-01 2015-10-21 康塞特医药品公司 吗啡烷化合物
PL3825306T3 (pl) 2007-05-01 2023-09-11 Sun Pharmaceutical Industries, Inc. Związki morfinanu
WO2008156632A1 (fr) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Dérivés d'azapeptides
WO2009051782A1 (fr) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Étravirine deutérée
CA2702935A1 (fr) * 2007-10-19 2009-04-23 Purdue Research Foundation Formulations solides de composes cristallins
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
AU2009217680B2 (en) 2008-02-29 2013-09-05 Concert Pharmaceuticals, Inc Substituted xanthine derivatives
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
WO2010019557A1 (fr) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. Dérivés n-phényl-2-pyrimidineamine
DK3248978T3 (da) 2008-09-19 2019-11-18 Concert Pharmaceuticals Inc Deutererede morphinanforbindelser
PL2397158T3 (pl) 2008-10-30 2016-09-30 Skojarzone podawanie związków morfinanów oraz leków przeciwdepresyjnych w leczeniu nietrzymania afektu
WO2010062690A1 (fr) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combinaison de composés de morphinane et d’antidépresseur pour le traitement de l’affect pseudobulbaire, des maladies neurologiques, de la douleur incurable et chronique et des lésions cérébrales
CN103396473A (zh) 2008-11-04 2013-11-20 安科治疗公司 Cxcr4受体化合物
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
EP2454259A1 (fr) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Dérivés de triazolo-pyridazine modifiés par deutérium comme modulateurs du récepteur gaba-a
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (fr) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Benzimidazoles substitués
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (fr) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Azaindoles substitués
EP2536696A1 (fr) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Dérivés de la pyrimidine
EP2566494B1 (fr) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Composés de récepteur cxcr4
EP2542534A1 (fr) 2010-03-02 2013-01-09 Concert Pharmaceuticals Inc. Dérivés de tétrahydronaphtalène deutérés
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US20130116239A1 (en) 2010-06-14 2013-05-09 ratiopharm GnbH Ivabradine-containing pharmaceutical composition with modified release
US20120208837A1 (en) 2010-09-13 2012-08-16 Roger Tung Substituted azaindoles
EP2455068A1 (fr) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Composition pharmaceutique pour le traitement d'infections par VHC
WO2012065028A2 (fr) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Tétracyclines substituées
WO2012079075A1 (fr) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Dérivés de phtalimide deutérés
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
JP2014506603A (ja) 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
WO2012129381A1 (fr) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Preladenant deutéré
WO2012151361A1 (fr) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Dérivés de carbamoylpyridone
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
PL2709986T3 (pl) 2011-05-18 2017-09-29 Concert Pharmaceuticals Inc. Deuterowane pochodne iwakaftoru
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
CA2860740A1 (fr) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Composes de recepteurs apj
WO2013130849A1 (fr) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Dérivés de phthalimide dioxopipéridinyle substitués
EP2836492B1 (fr) 2012-04-13 2018-03-14 Concert Pharmaceuticals Inc. Dérivés de xanthine substituée
WO2013159026A1 (fr) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Rigosertib deutéré
ES2867048T3 (es) 2012-06-15 2021-10-20 Concert Pharmaceuticals Inc Derivados deuterados de ruxolitinib
CA2908929C (fr) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Idebenone deuteree
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
WO2014078842A1 (fr) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Potentialisateurs de cftr deutérés
US20150299166A1 (en) 2012-12-20 2015-10-22 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
US9789126B2 (en) 2012-12-21 2017-10-17 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (fr) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Dérivés substitués de dioxopipéridinyl phtalimide
WO2014150043A1 (fr) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibiteurs de l'enzyme udp-glucose : n-acyl-sphingosine glucosyltransférase
AU2014235462C1 (en) 2013-03-15 2018-11-01 Concert Pharmaceuticals, Inc. Deuterated palbociclib
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (fr) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Dérivés deutériés d'intédanib et leur utilisation pour le traitement de troubles prolifératifs
WO2015010045A1 (fr) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Composés de récepteurs apj
WO2015031741A1 (fr) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Thiénotriazolodiazépines substituées
JP6526060B2 (ja) 2014-02-10 2019-06-05 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロベンゾジアゼピン
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (fr) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Composés phénylquinazolinone et phénylisoquinolinone deutérés
CN106459004B (zh) 2014-06-06 2020-09-15 研究三角协会 爱帕琳肽受体(apj)激动剂及其用途
WO2016022955A1 (fr) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Composés et méthodes de traitement du cancer
WO2016061488A1 (fr) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Inhibiteurs de réabsorption d'amines
WO2016073545A1 (fr) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Acides benzoïques de phényloxadiazole
WO2016089814A1 (fr) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Analogues deutériés du daclatasvir
WO2016094011A1 (fr) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Formes cristallines d'un antagoniste de ccr5
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (fr) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Dasabuvir deutéré
WO2016109795A1 (fr) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Funapide et difluorofunapide deutérés
EP3265440A1 (fr) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Emricasan deutéré
WO2016160945A1 (fr) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Vx-661 deutéré
WO2016176335A1 (fr) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Otx-015 deutéré
WO2017020005A1 (fr) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Composés de morphinane utilisés pour le traitement de l'agitation
US20180243289A1 (en) 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
EP3377179B1 (fr) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Epi-743 deutéré
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
WO2017147003A1 (fr) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Nouveaux antibiotiques macrocycliques et leurs utilisations
HRP20241345T1 (hr) 2016-05-04 2024-12-20 Sun Pharmaceutical Industries, Inc. Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak
PT3825307T (pt) 2016-07-04 2022-08-26 Avanir Pharmaceuticals Inc Métodos para a síntese de dextrometorfano deuterado
EP3490538A4 (fr) 2016-08-01 2020-03-18 The Brigham and Women's Hospital, Inc. Particules pour l'administration de protéines et de peptides
WO2018119076A1 (fr) 2016-12-21 2018-06-28 Research Triangle Institute Dérivés de diarylpurine présentant une biodisponibilité améliorée
ES3036483T3 (en) 2017-02-28 2025-09-19 Mayo Found Medical Education & Res Combinations for use in the treatment of cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
CA3063953A1 (fr) 2017-05-19 2018-11-22 Superb Wisdom Limited Derives de resiquimod
AU2018371784B2 (en) 2017-11-22 2024-10-17 Sun Pharmaceutical Industries, Inc. Deuterated analogs of D-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
KR20210150495A (ko) 2019-04-10 2021-12-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료
WO2021236139A1 (fr) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Nouvel inhibiteur de jak deutéré et ses utilisations
WO2021243015A1 (fr) 2020-05-27 2021-12-02 The Penn State Research Foundation Composés antibactériens
EP4236956A1 (fr) 2020-10-28 2023-09-06 Sun Pharmaceutical Industries, Inc. Régimes pour le traitement de troubles liés à la perte des cheveux avec des inhibiteurs de jak deutérés
AU2022225215A1 (en) 2021-02-25 2023-08-31 Research Triangle Institute Heteroaryl derivatives as apelin receptor agonists
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (fr) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Traitement de troubles sensibles à l'inhibition de jak avec des promédicaments d'inhibiteurs de jak
US20250275977A1 (en) 2022-05-04 2025-09-04 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
WO1998057648A1 (fr) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Procede d'amelioration de la biodisponibilite des polymorphes cristallins stables d'un compose
EP1028712B1 (fr) * 1997-09-19 2005-01-12 Shire Laboratories Inc. Granule de solution solide
ES2235991T3 (es) * 1999-11-12 2005-07-16 Abbott Laboratories Formulaciones farmaceuticas de dispersion solida.
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
CZ20033211A3 (cs) 2004-09-15
HRP20030873B1 (en) 2006-04-30
IL158306A (en) 2008-11-03
SK14572003A3 (sk) 2004-12-01
US20030021840A1 (en) 2003-01-30
HRP20030873A2 (en) 2005-08-31
JP4101661B2 (ja) 2008-06-18
AR034320A1 (es) 2004-02-18
PE20021159A1 (es) 2002-12-20
TWI234461B (en) 2005-06-21
PL366998A1 (en) 2005-02-07
CA2444116C (fr) 2009-01-20
JP2004527569A (ja) 2004-09-09
EP1390063B1 (fr) 2004-11-17
CN1255185C (zh) 2006-05-10
BG108311A (bg) 2004-12-30
BR0209325A (pt) 2004-07-20
CA2444116A1 (fr) 2002-11-14
ES2231717T3 (es) 2005-05-16
KR100554816B1 (ko) 2006-02-22
HUP0401238A3 (en) 2012-09-28
NO20034689L (no) 2003-10-20
NZ528689A (en) 2005-03-24
WO2002089835A3 (fr) 2003-05-01
HU229938B1 (en) 2015-01-28
GEP20053466B (en) 2005-02-25
KR20040007523A (ko) 2004-01-24
DE60201988T2 (de) 2005-12-15
PT1390063E (pt) 2005-03-31
IL158306A0 (en) 2004-05-12
PA8544501A1 (es) 2002-11-18
DE60201988D1 (de) 2004-12-23
EP1390063A2 (fr) 2004-02-25
IS7010A (is) 2003-10-30
US7014866B2 (en) 2006-03-21
HUP0401238A2 (hu) 2004-12-28
JO2401B1 (en) 2007-06-17
CN1547484A (zh) 2004-11-17
GT200200079A (es) 2002-12-05
EA200301166A1 (ru) 2004-04-29
ECSP034827A (es) 2003-12-24
HK1070285A1 (en) 2005-06-17
ATE282428T1 (de) 2004-12-15
WO2002089835A2 (fr) 2002-11-14
NO20034689D0 (no) 2003-10-20
MXPA03009971A (es) 2004-02-12
MY128509A (en) 2007-02-28
EA006627B1 (ru) 2006-02-24
UA76463C2 (en) 2006-08-15
RS83503A (sr) 2006-10-27

Similar Documents

Publication Publication Date Title
MA27018A1 (fr) Forme dosifiee pharmaceutique de mesylate de nelfinavir amorphe.
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
DK1395242T3 (da) Flydende farmaceutisk sammensætning
ITTO20010005A1 (it) Formulazione farmaceutica.
NO20033384D0 (no) Farmasöytisk formulering
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
FI20011478A0 (fi) Farmaseuttinen koostumus
NO20033785D0 (no) Farmasöytisk formulering
EE05020B1 (et) Glburiidi ravimkoostis
MXPA03001425A (es) Compuestos farmaceuticos.
NO20035627D0 (no) Farmasöytisk formulering
EP1408896A4 (fr) Composition pharmaceutique
FI20022128A0 (fi) Farmaseuttinen koostumus
FR2817750B1 (fr) Composition pharmaceutique de dronedarone pour administration parenterale
NO20033162L (no) Farmasöytisk tablett omfattende paroksetinmesylat
NO20015534D0 (no) Farmasöytisk blandeapparat
NO20033073L (no) Farmasöytisk sammensetning inneholdende citalopram
DK1390063T3 (da) Farmaceutisk doseringsform af amorft nelfinavir-mesylat
NO20041236L (no) Farmasoytisk formulering
SE0102572D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation